Clinical and biological features of t(4;14) multiple myeloma: a prospective study (Q57217664)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21261498%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

title

Clinical and biological features of t(4;14) multiple myeloma: a prospective study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21261498%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21261498%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Raphaël Porcher

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21261498%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Olivier Hermine

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21261498%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

author name string

Lionel Karlin

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21261498%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Jean Soulier

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21261498%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Olivia Chandesris

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21261498%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Sylvain Choquet

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21261498%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Karim Belhadj

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21261498%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Margaret Macro

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21261498%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

David Ghez

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21261498%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Marion Malphettes

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21261498%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Bouchra Asli

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21261498%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Jean Claude Brouet

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21261498%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Jean Christophe Bories

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21261498%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Jean Paul Fermand

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21261498%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Bertrand Arnulf

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21261498%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

publication date

24 January 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21261498%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21261498%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

volume

52

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21261498%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21261498%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

page(s)

238-246

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21261498%20AND%20SRC:MED&resulttype=core&format=json

Early genetic events provide the basis for a clinical classification of multiple myeloma.

20 January 2020

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.537795

Detection and follow-up of fibroblast growth factor receptor 3 expression on bone marrow and circulating plasma cells by flow cytometry in patients with t(4;14) multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.537795

The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.537795

International uniform response criteria for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.537795

Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.537795

Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.537795

Single versus double autologous stem-cell transplantation for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.537795

Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.537795

Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.537795

Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.537795

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.537795

Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.537795

Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.537795

The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.537795

Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.537795

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.537795

Do beta2 microglobulin levels affect survival of newly diagnosed myeloma patients with translocation t(4;14) or 17p13 deletion treated with conventional chemotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.537795

CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.537795

CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.537795

The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.537795

10.3109/10428194.2010.537795

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21261498%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference